Ipsen Announces Executive Committee Changes and Buy-Back Programme

Ipsen announced changes to its Executive Committee, including Mari Scheiffele as its new Chief Commercial Officer. Scheiffele will be responsible for the company's commercial strategy and operations. Ipsen also announced a buy-back programme to purchase up to 6% of its shares in 2025. The programme is subject to market conditions and regulatory approvals.

Exelixis, Inc. (Nasdaq: EXEL) reported its financial results for the second quarter of 2025, highlighting strong performance in its Cabozantinib franchise and progress in clinical trials. Total revenues for the quarter ended June 30, 2025, were $568.3 million, compared to $637.2 million in the same period last year. Net product revenues, primarily driven by the Cabozantinib franchise, reached $520.0 million, up from $437.6 million in the same period last year.

The company's Chief Executive Officer, Michael M. Morrissey, Ph.D., noted the successful launch of CABOMETYX® in advanced neuroendocrine tumors (NET) in the U.S. and the positive top-line results from the STELLAR-303 pivotal study in colorectal cancer. Exelixis plans to discuss these results with regulators and aims to file for approval in this indication as quickly as possible.

Ipsen, a collaboration partner of Exelixis, also made significant announcements. The company appointed Mari Scheiffele as its new Chief Commercial Officer, responsible for the company's commercial strategy and operations. Additionally, Ipsen announced a share buyback program to purchase up to 6% of its shares in 2025, subject to market conditions and regulatory approvals.

Exelixis' research and development expenses decreased to $200.4 million from $211.1 million in the same period last year, primarily due to decreases in manufacturing costs and clinical trial costs. Selling, general, and administrative expenses increased to $134.9 million from $132.0 million, driven by increases in marketing expenses and stock-based compensation.

Exelixis maintains its previously provided financial guidance for fiscal year 2025, with total revenues expected to be between $2.25 billion and $2.35 billion, and net product revenues between $2.05 billion and $2.15 billion.

References:
[1] https://www.biospace.com/press-releases/exelixis-announces-second-quarter-2025-financial-results-and-provides-corporate-update